Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SF3B3 (ImmuneEditome ID:23450)

1. Gene summary of enriched editing regions for SF3B3

Gene summary

Gene information	Gene symbol	SF3B3
	Gene ID	23450
	GeneSynonyms	RSE1\|SAP130\|SF3b130\|STAF130
	GeneCytomap	16q22.1
	GeneType	protein-coding
	GeneDescription	splicing factor 3B subunit 3\|SAP 130\|pre-mRNA splicing factor SF3b, 130 kDa subunit\|spliceosome-associated protein 130
	GeneModificationdate	20230409
	UniprotID	Q15393;H3BMB0;J3QKV4;J3QL37;I3L4G7;J3QRB2
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr16:70525703-70526396:+	ENST00000302516.8	ENSG00000189091.11	SF3B3	intronic	AluY,AluSg	chr16:70525703-70526396:+.alignment
chr16:70525703-70526396:+	ENST00000564899.1	ENSG00000189091.11	SF3B3	intronic	AluY,AluSg	chr16:70525703-70526396:+.alignment
chr16:70525703-70526396:+	ENST00000566095.5	ENSG00000189091.11	SF3B3	intronic	AluY,AluSg	chr16:70525703-70526396:+.alignment
chr16:70525703-70526396:+	ENST00000567654.1	ENSG00000189091.11	SF3B3	intronic	AluY,AluSg	chr16:70525703-70526396:+.alignment
chr16:70525703-70526396:+	ENST00000577085.1	ENSG00000189091.11	SF3B3	intronic	AluY,AluSg	chr16:70525703-70526396:+.alignment
chr16:70574274-70577097:+	ENST00000562874.2	ENSG00000189091.11	SF3B3	ncRNA_exonic	L2b,AluSx,AluJo,AluSz6,AluJr,MIRc	chr16:70574274-70577097:+.alignment

Top

2. Tumor-specific enriched editing regions for SF3B3

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000189091.11,SF3B3	PAAD	Path	EAG	3.9381e-02	2.8194e-02	0.3237
chr16:70574274-70577097:+	TGCT	Path	EER	4.9769e-02	2.3780e-02	-0.2892
ENSG00000189091.11,SF3B3	UCS	Cli	EAG	2.5024e-02	1.8761e-02	-0.3491

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr16:70574274-70577097:+	KIRC	EER	1.3095e-02	4.8354e-02	8.9504e+00
ENSG00000189091.11,SF3B3	KIRC	EAG	1.3095e-02	4.8367e-02	8.9394e+00

Top

3. Enriched editing regions and immune related genes for SF3B3

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr16:70574274-70577097:+

GBM

EER

ENSG00000071564,TCF3

-0.5144

4.3225e-07

1.4726e-09

-0.4686

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1

TCF3

Monocytes

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr16:70574274-70577097:+

GBM

EER

ENSG00000011451,WIZ

-0.5132

4.6155e-07

1.0698e-10

-0.4962

ACIN1;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

Monocytes

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr16:70574274-70577097:+

GBM

EER

ENSG00000121210,KIAA0922

-0.5095

6.1185e-07

2.5820e-08

-0.4354

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TROVE2;U2AF2;UPF1

Monocytes

GSVA_HALLMARK_BILE_ACID_METABOLISM

chr16:70574274-70577097:+

GBM

EER

ENSG00000189091,SF3B3

-0.4850

2.9589e-06

4.0166e-09

-0.4574

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

Monocytes

GSVA_HALLMARK_MITOTIC_SPINDLE

chr16:70574274-70577097:+

GBM

EER

ENSG00000167491,GATAD2A

-0.4828

3.5570e-06

2.8349e-09

-0.4613

ACIN1;ADAR;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1

Monocytes

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr16:70574274-70577097:+

GBM

EER

ENSG00000148655,C10orf11

0.4720

4.5755e-06

1.6388e-11

0.5145

ACIN1;ADAR;BCCIP;CSTF2T;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SF3A3;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TROVE2;U2AF2;UPF1

Monocytes

GSVA_HALLMARK_MITOTIC_SPINDLE

chr16:70574274-70577097:+

GBM

EER

ENSG00000089094,KDM2B

-0.4721

5.8839e-06

7.0297e-08

-0.4228

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

Monocytes

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr16:70574274-70577097:+

GBM

EER

ENSG00000108671,PSMD11

-0.4722

5.8839e-06

6.2070e-09

-0.4523

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

PSMD11

Monocytes

GSVA_HALLMARK_G2M_CHECKPOINT

chr16:70574274-70577097:+

GBM

EER

ENSG00000165661,QSOX2

-0.4738

5.8984e-06

6.9528e-08

-0.4230

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

T_cells_follicular_helper

GSVA_HALLMARK_G2M_CHECKPOINT

chr16:70574274-70577097:+

GBM

EER

ENSG00000176619,LMNB2

-0.4738

5.9790e-06

2.8457e-07

-0.4045

ACIN1;ADAR;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

Macrophages_M0

GSVA_HALLMARK_G2M_CHECKPOINT

More results

Top

4. Enriched editing regions and immune related splicing for SF3B3

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr16:70574274-70577097:+

ESCA

EER

ENSG00000108854.11

chr17

64578491:64578576:64580788:64580991

0.3482

3.3546e-02

2.5955e-07

0.4161

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1

SMURF2

T_cells_CD4_memory_activated

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000172939.4

chr3

38251402:38252392:38252816:38255488

0.3864

8.0555e-03

6.2628e-10

0.4793

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZC3H7B;ZNF184

OXSR1

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000121060.10

chr17

56891363:56895952:56899114:56899180

0.3512

2.6224e-02

1.4179e-08

0.4440

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MBNL2;METTL14;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZC3H7B;ZNF184

TRIM25

T_cells_CD4_memory_resting

GSVA_HALLMARK_MYC_TARGETS_V1

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000135912.6

chr2

218745994:218746231:218747029:218747194

0.3167

1.3672e-02

1.1072e-05

0.4055

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000123815.7

chr19

40705095:40705181:40705324:40705447

0.3544

2.6230e-02

1.2703e-07

0.4165

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

T_cells_CD4_memory_activated

GSVA_HALLMARK_PEROXISOME

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000096433.6

chr6

33691782:33691928:33692727:33692893

0.3868

8.1137e-03

5.8122e-08

0.4266

ACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL1;METTL14;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;WTAP;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

ITPR3

T_cells_CD4_memory_activated

GSVA_HALLMARK_GLYCOLYSIS

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000142675.13

chr1

26182360:26182402:26182479:26182563

0.3493

2.6341e-02

2.7735e-08

0.4385

AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;KHDRBS1;KHSRP;LSM11;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

ENSG00000189091.11,SF3B3

ESCA

EAG

ENSG00000142765.13

chr1

27349397:27350132:27350388:27350485

0.3818

8.1441e-03

1.3562e-07

0.4196

ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28A;LIN28B;LSM11;METTL14;METTL3;NONO;NOP58;NPM1;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;WTAP;XRN2;ZNF184

SYTL1

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr16:70574274-70577097:+

ESCA

EER

ENSG00000196850.4

chr12

110531314:110537095:110538143:110538273

0.4096

3.9226e-03

6.6266e-08

0.4344

ACIN1;ADAR;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28B;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

Neutrophils

GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING

chr16:70574274-70577097:+

ESCA

EER

ENSG00000110697.8

chr11

67498132:67498322:67498595:67498846

0.3474

3.4104e-02

7.5362e-07

0.4011

ACIN1;ADAR;ALYREF;BCCIP;BUD13;CELF2;CSTF2T;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YWHAG

GSVA_HALLMARK_HEME_METABOLISM

More results

Top

5. Enriched editing regions and immune infiltration for SF3B3

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000189091.11,SF3B3	ACC	EAG	NK_cells_activated	3.5193e-02	0.2680
chr16:70574274-70577097:+	BLCA	EER	T_cells_CD8	3.8635e-02	0.1534
chr16:70574274-70577097:+	BRCA	EER	Mast_cells_resting	2.0033e-10	0.2337
ENSG00000189091.11,SF3B3	BRCA	EAG	Mast_cells_resting	4.8593e-10	0.2280
chr16:70574274-70577097:+	CESC	EER	Dendritic_cells_activated	8.0142e-03	0.2016
ENSG00000189091.11,SF3B3	CESC	EAG	T_cells_regulatory_(Tregs)	1.0028e-02	-0.1931
chr16:70574274-70577097:+	COAD	EER	Dendritic_cells_activated	1.8451e-02	0.2185
ENSG00000189091.11,SF3B3	COAD	EAG	Dendritic_cells_activated	9.8976e-06	0.3868
chr16:70574274-70577097:+	DLBC	EER	B_cells_memory	4.9523e-02	-0.3890
ENSG00000189091.11,SF3B3	DLBC	EAG	Plasma_cells	4.5774e-02	0.3805
chr16:70574274-70577097:+	ESCA	EER	Neutrophils	1.2439e-02	-0.2093
ENSG00000189091.11,SF3B3	ESCA	EAG	NK_cells_activated	4.3568e-02	0.1656
chr16:70574274-70577097:+	GBM	EER	T_cells_CD8	5.0748e-04	0.2805
ENSG00000189091.11,SF3B3	GBM	EAG	T_cells_CD8	3.4402e-04	0.2884
chr16:70574274-70577097:+	HNSC	EER	T_cells_follicular_helper	1.0456e-03	-0.2215
ENSG00000189091.11,SF3B3	HNSC	EAG	T_cells_follicular_helper	2.3793e-03	-0.2034
chr16:70574274-70577097:+	KICH	EER	T_cells_follicular_helper	3.8303e-02	-0.2939
ENSG00000189091.11,SF3B3	KICH	EAG	T_cells_follicular_helper	3.8303e-02	-0.2939
chr16:70574274-70577097:+	KIRC	EER	Monocytes	5.4448e-03	-0.1678
ENSG00000189091.11,SF3B3	KIRC	EAG	Monocytes	5.5700e-03	-0.1671
ENSG00000189091.11,SF3B3	LAML	EAG	Monocytes	1.6212e-03	0.5424
chr16:70574274-70577097:+	LGG	EER	T_cells_CD4_memory_activated	5.2614e-04	0.1517
ENSG00000189091.11,SF3B3	LGG	EAG	T_cells_CD4_memory_activated	5.4899e-04	0.1512
chr16:70574274-70577097:+	LIHC	EER	Neutrophils	2.5767e-02	0.3217
ENSG00000189091.11,SF3B3	LIHC	EAG	Neutrophils	2.5767e-02	0.3217
ENSG00000189091.11,SF3B3	LUAD	EAG	T_cells_CD4_memory_activated	2.7581e-03	0.2263
chr16:70574274-70577097:+	LUSC	EER	B_cells_naive	2.0353e-02	-0.1319
ENSG00000189091.11,SF3B3	LUSC	EAG	B_cells_naive	1.8892e-02	-0.1333
ENSG00000189091.11,SF3B3	PAAD	EAG	Neutrophils	7.9715e-03	0.3786
chr16:70574274-70577097:+	PCPG	EER	Dendritic_cells_activated	3.3619e-02	0.1660
ENSG00000189091.11,SF3B3	PCPG	EAG	Dendritic_cells_activated	3.3619e-02	0.1660
ENSG00000189091.11,SF3B3	PRAD	EAG	Eosinophils	2.9062e-02	0.1324
chr16:70574274-70577097:+	READ	EER	Mast_cells_resting	1.8800e-02	-0.3794
ENSG00000189091.11,SF3B3	READ	EAG	Mast_cells_resting	3.5964e-02	-0.3369
chr16:70574274-70577097:+	SKCM	EER	T_cells_regulatory_(Tregs)	3.1787e-02	0.1208
ENSG00000189091.11,SF3B3	SKCM	EAG	T_cells_regulatory_(Tregs)	3.4946e-02	0.1185
chr16:70525703-70526396:+	STAD	EER	Dendritic_cells_resting	2.2926e-02	0.2076
ENSG00000189091.11,SF3B3	STAD	EAG	NK_cells_resting	1.6428e-02	-0.1435
chr16:70574274-70577097:+	TGCT	EER	Plasma_cells	7.7768e-04	0.3015
ENSG00000189091.11,SF3B3	TGCT	EAG	Plasma_cells	1.5236e-03	0.2796
ENSG00000189091.11,SF3B3	THCA	EAG	T_cells_CD4_memory_activated	7.9692e-03	0.1359
chr16:70574274-70577097:+	THYM	EER	Dendritic_cells_activated	3.7907e-03	0.2764
ENSG00000189091.11,SF3B3	THYM	EAG	Dendritic_cells_activated	2.1054e-04	0.3494
chr16:70574274-70577097:+	UCEC	EER	T_cells_CD8	2.1358e-02	-0.2539
ENSG00000189091.11,SF3B3	UCS	EAG	Neutrophils	1.4425e-02	0.3624
chr16:70574274-70577097:+	UVM	EER	T_cells_gamma_delta	8.3156e-04	0.3959
ENSG00000189091.11,SF3B3	UVM	EAG	T_cells_gamma_delta	8.3156e-04	0.3959

Top

6. Enriched editing regions and immune gene sets for SF3B3

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000189091.11,SF3B3	LGG	EAG	1.3489e-04	-0.1668	1.1731e-04	-0.1683	1.4476e-05	-0.1891	3.2642e-02	0.0938
chr16:70574274-70577097:+	LGG	EER	1.5228e-04	-0.1655	1.1561e-04	-0.1684	1.3195e-05	-0.1900	3.3815e-02	0.0932

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000189091.11,SF3B3	ACC	GSVA_HALLMARK_DNA_REPAIR	EAG	2.6861e-02	-0.2811
ENSG00000189091.11,SF3B3	BLCA	GSVA_HALLMARK_APICAL_SURFACE	EAG	2.0617e-02	0.1696
chr16:70574274-70577097:+	BLCA	GSVA_HALLMARK_APICAL_SURFACE	EER	1.2453e-02	0.1849
ENSG00000189091.11,SF3B3	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.6087e-07	0.1927
chr16:70574274-70577097:+	BRCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	2.1010e-08	0.2065
chr16:70574274-70577097:+	CESC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	4.2809e-04	0.2657
ENSG00000189091.11,SF3B3	CESC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	4.6402e-04	0.2604
ENSG00000189091.11,SF3B3	COAD	GSVA_HALLMARK_DNA_REPAIR	EAG	1.5475e-03	-0.2825
chr16:70574274-70577097:+	DLBC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	1.2941e-02	-0.4806
ENSG00000189091.11,SF3B3	DLBC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	2.4649e-02	-0.4237
chr16:70574274-70577097:+	ESCA	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	5.8934e-03	0.2300
ENSG00000189091.11,SF3B3	ESCA	GSVA_HALLMARK_PEROXISOME	EAG	1.0569e-02	-0.2089
chr16:70574274-70577097:+	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.3762e-06	-0.3823
ENSG00000189091.11,SF3B3	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.9283e-06	-0.3774
ENSG00000189091.11,SF3B3	HNSC	GSVA_HALLMARK_MYOGENESIS	EAG	1.1171e-03	0.2178
chr16:70574274-70577097:+	HNSC	GSVA_HALLMARK_MYOGENESIS	EER	7.6033e-04	0.2274
ENSG00000189091.11,SF3B3	KICH	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	1.2473e-03	0.4438
chr16:70574274-70577097:+	KICH	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	1.2473e-03	0.4438
ENSG00000189091.11,SF3B3	KIRC	GSVA_HALLMARK_COAGULATION	EAG	1.8520e-04	0.2240
chr16:70574274-70577097:+	KIRC	GSVA_HALLMARK_COAGULATION	EER	1.6688e-04	0.2259
ENSG00000189091.11,SF3B3	LAML	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	3.4438e-03	-0.5091
chr16:70574274-70577097:+	LGG	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.1321e-13	-0.3182
ENSG00000189091.11,SF3B3	LGG	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	8.7372e-14	-0.3196
ENSG00000189091.11,SF3B3	LIHC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	3.4255e-03	0.4142
chr16:70574274-70577097:+	LIHC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.4255e-03	0.4142
chr16:70574274-70577097:+	LUAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.5753e-03	0.2236
ENSG00000189091.11,SF3B3	LUAD	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.8272e-02	0.1793
ENSG00000189091.11,SF3B3	LUSC	GSVA_HALLMARK_COAGULATION	EAG	2.6456e-04	0.2058
chr16:70574274-70577097:+	LUSC	GSVA_HALLMARK_COAGULATION	EER	1.8180e-04	0.2114
ENSG00000189091.11,SF3B3	MESO	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EAG	7.8218e-03	0.3582
chr16:70574274-70577097:+	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.8393e-03	-0.1955
ENSG00000189091.11,SF3B3	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.2197e-03	-0.2052
ENSG00000189091.11,SF3B3	PAAD	GSVA_HALLMARK_DNA_REPAIR	EAG	1.4089e-02	-0.3522
ENSG00000189091.11,SF3B3	PCPG	GSVA_HALLMARK_DNA_REPAIR	EAG	2.5502e-03	-0.2341
chr16:70574274-70577097:+	PCPG	GSVA_HALLMARK_DNA_REPAIR	EER	2.5502e-03	-0.2341
ENSG00000189091.11,SF3B3	PRAD	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	2.5302e-02	-0.1356
chr16:70574274-70577097:+	READ	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.5871e-02	-0.3887
ENSG00000189091.11,SF3B3	READ	GSVA_HALLMARK_SPERMATOGENESIS	EAG	3.2759e-02	-0.3426
chr16:70574274-70577097:+	SARC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	4.9424e-03	-0.2122
ENSG00000189091.11,SF3B3	SARC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	4.9424e-03	-0.2122
ENSG00000189091.11,SF3B3	SKCM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	3.0960e-04	0.2013
chr16:70574274-70577097:+	SKCM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	3.2847e-04	0.2008
chr16:70574274-70577097:+	STAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	8.2515e-03	-0.1681
chr16:70525703-70526396:+	STAD	GSVA_HALLMARK_APICAL_JUNCTION	EER	2.0303e-08	0.4847
ENSG00000189091.11,SF3B3	STAD	GSVA_HALLMARK_COMPLEMENT	EAG	2.2430e-04	0.2192
chr16:70574274-70577097:+	TGCT	GSVA_HALLMARK_G2M_CHECKPOINT	EER	2.4640e-02	-0.2042
ENSG00000189091.11,SF3B3	THCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	3.4292e-04	0.1827
chr16:70574274-70577097:+	THYM	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.2766e-03	0.3060
ENSG00000189091.11,SF3B3	THYM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.9699e-03	0.2946
ENSG00000189091.11,SF3B3	UCS	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.5632e-02	0.3584
ENSG00000189091.11,SF3B3	UVM	GSVA_HALLMARK_COAGULATION	EAG	4.4013e-02	0.2450
chr16:70574274-70577097:+	UVM	GSVA_HALLMARK_COAGULATION	EER	4.4013e-02	0.2450

Top

7. Enriched editing regions and drugs for SF3B3

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000189091.11,SF3B3	ACC	AZD7762	EAG	2.0150e-02	0.2945
ENSG00000189091.11,SF3B3	BLCA	EHT.1864	EAG	5.3054e-03	0.2036
chr16:70574274-70577097:+	BLCA	Lapatinib	EER	4.9359e-03	-0.2075
ENSG00000189091.11,SF3B3	BRCA	CMK	EAG	2.0087e-06	0.1752
chr16:70574274-70577097:+	BRCA	CMK	EER	3.8314e-07	0.1876
chr16:70574274-70577097:+	CESC	EHT.1864	EER	3.5992e-03	0.2208
ENSG00000189091.11,SF3B3	CESC	EHT.1864	EAG	4.1414e-03	0.2145
chr16:70574274-70577097:+	COAD	Lenalidomide	EER	7.4224e-04	-0.3089
ENSG00000189091.11,SF3B3	COAD	Lenalidomide	EAG	3.1265e-05	-0.3661
ENSG00000189091.11,SF3B3	DLBC	Lenalidomide	EAG	1.1293e-02	-0.4716
chr16:70574274-70577097:+	DLBC	FTI.277	EER	4.1538e-03	0.5430
ENSG00000189091.11,SF3B3	ESCA	FH535	EAG	4.2890e-02	0.1661
chr16:70574274-70577097:+	ESCA	GDC.0449	EER	1.4618e-02	-0.2053
ENSG00000189091.11,SF3B3	GBM	BAY.61.3606	EAG	2.4000e-07	0.4068
chr16:70574274-70577097:+	GBM	BAY.61.3606	EER	1.0236e-07	0.4180
ENSG00000189091.11,SF3B3	HNSC	AZD.0530	EAG	3.8080e-04	-0.2375
chr16:70574274-70577097:+	HNSC	Bexarotene	EER	1.7658e-04	-0.2525
chr16:70574274-70577097:+	KICH	MG.132	EER	2.4464e-03	-0.4192
ENSG00000189091.11,SF3B3	KICH	MG.132	EAG	2.4464e-03	-0.4192
ENSG00000189091.11,SF3B3	KIRC	GSK269962A	EAG	5.1133e-05	-0.2421
chr16:70574274-70577097:+	KIRC	GSK269962A	EER	2.0108e-05	-0.2549
ENSG00000189091.11,SF3B3	KIRP	AS601245	EAG	4.5269e-02	0.1516
ENSG00000189091.11,SF3B3	LAML	BI.2536	EAG	4.1293e-04	0.5952
chr16:70574274-70577097:+	LGG	Epothilone.B	EER	1.0002e-15	0.3425
ENSG00000189091.11,SF3B3	LGG	Epothilone.B	EAG	5.4374e-16	0.3454
ENSG00000189091.11,SF3B3	LIHC	CCT018159	EAG	2.4842e-03	0.4268
chr16:70574274-70577097:+	LIHC	CCT018159	EER	2.4842e-03	0.4268
chr16:70574274-70577097:+	LUAD	BI.D1870	EER	2.8987e-02	-0.1685
ENSG00000189091.11,SF3B3	LUAD	Bexarotene	EAG	2.3491e-02	0.1722
ENSG00000189091.11,SF3B3	LUSC	CGP.60474	EAG	4.2903e-05	-0.2302
chr16:70574274-70577097:+	LUSC	CGP.60474	EER	5.5485e-05	-0.2272
ENSG00000189091.11,SF3B3	MESO	AZD7762	EAG	2.9339e-02	-0.2967
chr16:70574274-70577097:+	OV	ABT.263	EER	3.4240e-03	0.1979
ENSG00000189091.11,SF3B3	OV	CHIR.99021	EAG	2.1750e-03	0.2056
ENSG00000189091.11,SF3B3	PAAD	GDC.0449	EAG	9.0730e-04	-0.4635
ENSG00000189091.11,SF3B3	PCPG	AICAR	EAG	2.8599e-04	0.2797
chr16:70574274-70577097:+	PCPG	AICAR	EER	2.8599e-04	0.2797
ENSG00000189091.11,SF3B3	PRAD	AS601245	EAG	8.3274e-03	-0.1597
chr16:70574274-70577097:+	READ	Erlotinib	EER	2.5958e-02	-0.3610
ENSG00000189091.11,SF3B3	READ	CGP.082996	EAG	3.0269e-02	0.3473
ENSG00000189091.11,SF3B3	SARC	Axitinib	EAG	6.3648e-03	0.2061
chr16:70574274-70577097:+	SARC	Axitinib	EER	6.3648e-03	0.2061
ENSG00000189091.11,SF3B3	SKCM	Doxorubicin	EAG	3.0753e-04	0.2014
chr16:70574274-70577097:+	SKCM	Doxorubicin	EER	1.8868e-04	0.2086
chr16:70574274-70577097:+	STAD	GSK.650394	EER	2.3575e-03	0.1930
chr16:70525703-70526396:+	STAD	AZ628	EER	4.5138e-05	-0.3634
ENSG00000189091.11,SF3B3	STAD	CI.1040	EAG	2.1360e-04	-0.2199
ENSG00000189091.11,SF3B3	THCA	Elesclomol	EAG	2.3673e-06	0.2394
chr16:70574274-70577097:+	THYM	AZD6244	EER	2.6874e-05	-0.3922
ENSG00000189091.11,SF3B3	THYM	GSK269962A	EAG	1.2595e-03	0.3064
ENSG00000189091.11,SF3B3	UCS	Cisplatin	EAG	2.3021e-03	-0.4431
ENSG00000189091.11,SF3B3	UVM	Cisplatin	EAG	2.2992e-03	-0.3637
chr16:70574274-70577097:+	UVM	Cisplatin	EER	2.2992e-03	-0.3637

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType